tbuckley/cabot-search huggingface dataset:
PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a <sup>177</sup>Lu-labeled αPD-L1 antibody
Authors: Jingyun Ren, Mengxin Xu, Junyi Chen, Jie Ding, Peipei Wang, Li Huo, Fang Li, Zhibo Liu
Journal: Theranostics (2020)

Rationale:The low response rate of immunotherapy, such as anti-PD-L1/PD-1 and anti-CTLA4, has limited its application to a wider population of cancer patients.One widely accepted view is that inflammation within the tumor microenvironment is low or ineffective for inducing the sufficient infiltration and/or activation of lymphocytes.Here, a highly tumor-selective anti-PD-L1 (αPD-L1) antibody was developed through PET imaging screening, and it was radiolabeled with Lu-177 for PD-L1-targeted radioimmunotherapy (RIT) and radiation-synergized immunotherapy.Methods: A series of αPD-L1 antibodies were radiolabeled with zirconium-89 for PET imaging to screen the most suitable antibodies for RIT.Mice were divided into an immunotherapy group, a RIT group and a radiation-synergized immunotherapy group to evaluate the therapeutic effect.Alterations in the tumor microenvironment after treatment were assessed using flow cytometry and immunofluorescence microscopy.Results: Radiation-synergistic RIT can achieve a significantly better therapeutic effect than immunotherapy or RIT alone.The dosages of the radiopharmaceuticals and αPD-L1 antibodies were reduced, the infiltration of CD4 + and CD8 + T cells in the tumor microenvironment was increased, and no side effects were observed.This radiation-synergistic RIT strategy successfully showed a strong synergistic effect with αPD-L1 checkpoint blockade therapy, at least in the mouse model.Conclusions: PET imaging of 89 Zr-labeled antibodies is an effective method for antibody screening.RIT with a 177 Lu-labeled αPD-L1 antibody could successfully upregulate antitumor immunity in the tumor microenvironment and turn "cold" tumors "hot" for immunotherapy.
In Vivo Evaluation of Bioabsorbable Fe‐35Mn‐1Ag: First Reports on In Vivo Hydrogen Gas Evolution in Fe‐Based Implants
Authors: Matthew Simon Dargusch, Jeffrey Venezuela, Ali Dehghan‐Manshadi, Sean Johnston, Nan Yang, Karine Mardon, Cora Lau, Rachel Allavena
Journal: Advanced Healthcare Materials (2020)

Abstract This work investigates the influence of Ag (1 wt%) on the mechanical properties, in vitro and in vivo corrosion, and biocompatibility of Fe‐35Mn. The microstructure of Fe‐35Mn‐1Ag possesses a uniform dispersion of discrete silver particles. Slight improvements in compressive properties are attributed to enhanced density and low porosity volume. Fe‐35Mn‐1Ag exhibits good in vitro and in vivo corrosion rate of Fe‐35Mn due to an increase in microgalvanic corrosion. Gas pockets, which originate from an inflammatory response to the implants, are observed in the rats after 4 weeks implantation but are undetectable after 12 weeks. No chronic toxicity is observed with the Fe‐35Mn‐1Ag, suggesting acceptable in vivo biocompatibility. The high corrosion rate of the alloy triggers an increased level of nonadverse tissue inflammatory responses 4 weeks after implantation, which subsequently subsides at 12 weeks. The Fe‐35Mn‐1Ag displays properties that are suitable for orthopedic applications.
Complications and mortality of typhoid fever: A global systematic review and meta-analysis
Authors: Christian S. Marchello, Megan Birkhold, John A. Crump
Journal: Journal of Infection (2020)

Updated estimates of the prevalence of complications and case fatality ratio (CFR) among typhoid fever patients are needed to understand disease burden.Articles published in PubMed and Web of Science from 1 January 1980 through 29 January 2020 were systematically reviewed for hospital or community-based non-surgical studies that used cultures of normally sterile sites, and hospital surgical studies of typhoid intestinal perforation (TIP) with intra- or post-operative findings suggestive of typhoid. Prevalence of 21 pre-selected recognized complications of typhoid fever, crude and median (interquartile range) CFR, and pooled CFR estimates using a random effects meta-analysis were calculated.Of 113 study sites, 106 (93.8%) were located in Asia and Africa, and 84 (74.3%) were non-surgical. Among non-surgical studies, 70 (83.3%) were hospital-based. Of 10,355 confirmed typhoid patients, 2,719 (26.3%) had complications. The pooled CFR estimate among non-surgical patients was 0.9% for the Asia region and 5.4% for the Africa region. Delay in care was significantly correlated with increased CFR in Asia (r = 0.84; p<0.01). Among surgical studies, the median CFR of TIP was 15.5% (6.7-24.1%) per study.Our findings identify considerable typhoid-associated illness and death that could be averted with prevention measures, including typhoid conjugate vaccine introduction.
"Triple" Combination of Targeting Methyltransferase, BCL-2 and PD-1 Facilitates Therapeutic Responses in Acute Myeloid Leukemia (AML)
Authors: Zhihong Zeng, Shelley Herbrich, Tianyu Cai, Antonio Cavazos, Taylor Manzella, Helen Ma, Vinitha Mary Kuruvilla, Kala Hayes, Jairo A. Matthews, Courtney D. DiNardo, Naval Daver, Marina Konopleva
Journal: Blood (2020)
Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies
Authors: Pamela C Egan, Emmanuelle Belanger, Orestis A. Panagiotou, Vinay B Rao, Aryeh Pelcovits, Thomas W. LeBlanc, Adam J Olszewski
Journal: Blood (2020)
Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial
Authors: Karin Fjorden, Sara Ekberg, Nevzeta Kuric, Karin Ekstroem Smedby, Ingemar Lagerlöf, Thomas S. Larsen, Judit M. Jørgensen, Peter de Nully Brown, Mats Jerkeman
Journal: Blood (2020)
Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures
Authors: Tamar Berger, Odil Giladi, Dafna Yahav, Haim Ben-Zvi, Oren Pasvolsky, Liat Shargian-Alon, Ofir Wolach, Uri Rozovski, Pia Raanani, Moshe Yeshurun
Journal: Blood (2020)
Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide
Authors: Omar Albanyan, Seongho Kim, Anupama Kottam, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti, Dipenkumar Modi
Journal: Blood (2020)
Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study
Authors: Maria Mateos, Sundar Jagannath, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Irina Kryachok, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim A Doronin, Ganna Usenko, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Philippe Moreau, Moshe Y. Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Thierry Facon, Michele Cavo, Yi Chai, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G Kauffman, Paul G. Richardson, Sebastian Grosicki
Journal: Blood (2020)
Abstract PO-066: Computational identification of key pathway and differentially-expressed gene signatures in ovarian cancer stem cells
Authors: Renata H. Fu, Yongsheng Bai, Qi-En Wang
Journal: Cancer Research (2020)

Abstract Many studies have demonstrated the causativeness of cancer stem cells (CSCs), which are able to self-renew, metastasize, differentiate, and resist chemotherapy. Although multiple cell surface markers have been used to identify and isolate cancer stem cells, their uncertainty makes these surface markers unreliable in identifying heterogeneous cancer stem cells. Some transcription factors have been shown to be overexpressed in CSCs residing in multiple types of cancers, and some pathways have been found to regulate CSC populations. However, since some CSCs do not express all of the identified genes, it is important to establish a panel of genes and pathways that can consistently distinguish CSCs. To determine a panel of consensus genes or pathways that can be used to recognize CSCs, we attempted to identify differentially expressed genes and enriched pathways in CSCs, which we call cancer stem cell signature. In this study, we employed two ovarian cancer RNA-seq data (GSE33874 and GSE82304) from the Gene Expression Omnibus (GEO) and considered genes with significant fold changes (|logFC|≥1). We used ComPath to identify pathways that are enriched in each of our selected RNA-seq datasets, then we developed a customized python script to reveal pathways commonly enriched in both datasets. We subsequently applied ComPath’s mapping catalog to elucidate equivalent or hierarchical relationships across common pathways from three different databases (KEGG, Reactome, and WikiPathways). In total, we identified 241 commonly upregulated genes and 96 commonly downregulated genes. We also present 30 equivalent relationships and 98 hierarchical relationships between pathways. Our results confirm several pathways that are reported to be involved in CSC regulation, such as the Wnt signaling pathway and the Hedgehog pathway. Furthermore, we also identified multiple pathways that have been previously associated with poor prognosis or high risk of ovarian cancer, such as the Prolactin signaling pathway and the coagulation cascade, indicating that these pathways may also be involved in the maintenance of ovarian cancer stem cells. We will continue to investigate ovarian CSC gene and pathway signatures by involving more RNA-seq data and pathway analysis databases. Citation Format: Renata H. Fu, Yongsheng Bai, Qi-En Wang. Computational identification of key pathway and differentially-expressed gene signatures in ovarian cancer stem cells [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-066.
Zebrafish Models to Study Inflammasome-Mediated Regulation of Hematopoiesis
Authors: Lola Rodríguez-Ruiz, Juan M. Lozano-Gil, Christophe Lachaud, Pablo Mesa-del-Castillo, María L. Cayuela, Diana García-Moreno, Ana B. Pérez-Oliva, Victoriano Mulero
Journal: Trends in Immunology (2020)
Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study
Authors: Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla
Journal: Blood (2020)
Abstract 284: Loss of Micu3 Confers Cardioprotection Against Cardiac Injury
Authors: Bao Puente, Junhui Sun, Maria Fergusson, Julia Liu, Anna Kosmach, Randi Parks, Danielle Springer, Chengyu Liu, Elizabeth Murphy
Journal: Circulation Research (2020)

Background: Mitochondrial calcium flux and signaling is integral to cardiac function and contraction. However, during pathologic conditions such as ischemic/reperfusion injury, mitochondrial calcium overload can induce the opening of the mitochondrial permeability transitioning pore (PTP), resulting in the collapse of mitochondrial membrane potential, ATP depletion, and generation of reactive oxygen species, all together leading to cell death. Hence, modulation of mitochondrial calcium and inhibition of the PTP is a promising target for cardioprotection and prevention of cardiomyocyte death. The mitochondrial calcium uniporter (MCU) complex mediates rapid mitochondrial calcium uptake. MICU3 is a regulator of the MCU complex and has been shown to be a highly potent stimulator of MCU-dependent calcium uptake in neuronal cells. We found that MICU3 is expressed in hearts and we therefore investigated the role of MICU3 in the heart. We examined the role of MICU3 in the development of hypertrophy and in a separate study we examined the response to ischemic-reperfusion (I/R) injury. Given its role in regulating mitochondrial calcium uptake, we hypothesized that loss of MICU3 confers protection against cardiac injury. Methods: Mice with global deletion of Micu3 (Micu3 -/- ) were created utilizing CRISPR-Cas9 technology. Adult knockout and littermate wild type mice were treated with Isoproterenol (15mg/kg/day) for two weeks to induce hypertrophy. Echocardiograms were performed at baseline and after treatment to assess changes in left ventricular size and function. I/R injury was studied using Langendorff ex vivo perfused heart system, exposing knockout and wild type hearts to 20 minutes of ischemia and 90 minutes of reperfusion. Hemodynamic data and infarct size were collected and compared. Student t-test and 2-way ANOVA were used for statistical analysis. Result: Micu3 -/- mice had normal cardiac function at baseline. There was no sex difference in cardiac function. Micu3 -/- mice continued to show normal function after 2 weeks of treatment with Isoproterenol, whereas wild type mice exhibited depressed function (median FS 35% vs. 24% p = 0.0001, EF 64% vs. 50% p = 0.0001). Wild type mice developed LV dilation from baseline (median 4.15mm vs. 4.57mm, p = 0.0014), whereas LV dimension remained stable in Micu3 -/- mice (median 4.12mm vs. 4.18mm, p= 0.9892). Micu3 - /- mice were also protected from I/R injury. Compared to wild types, Micu3 -/- hearts demonstrated less contractile dysfunction at end reperfusion (median rate pressure product 62% vs. 41%, p = 0.002), and significantly smaller infarct size (median 33% vs. 53%, p = 0.0001). Conclusion: Loss of MICU3 confers cardioprotection against ischemic reperfusion injury and Isoproterenol induced cardiac dysfunction.
RPA1 Gain of Function Causes Human Short Telomere Syndrome with Revertant Somatic Mosaicism
Authors: Richa Sharma, Sushree Sangita Sahoo, Masayoshi Honda, Charnise Goodings-Harris, Victor Pastor, Hauke Busch, Melanie Börries, Fabian Beier, Miriam Erlacher, Melchior Lauten, Marc Wold, Maria Spies, Charlotte M. Niemeyer, Marcin Wlodarski
Journal: Blood (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Authors: Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Robert T Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter, Iain Bennett, Stanislas Hubeaux, Ludwig Kappos, Stephen L Hauser
Journal: The Lancet Neurology (2020)
Abstract 203: Appropriate Utilization of the HEART Score Saves Money: A Community Hospital Perspective
Authors: Ly Tran, Charlie Ervin, Morgan Mickalis, Rachael Weigle, Rahul Sampath, Steven Isserman
Journal: Circulation Research (2020)

HEART Score (HS) is a risk stratification tool used in predicting major adverse cardiac events (MACE) in patients presenting with undifferentiated chest pain. It is calculated by attributing zero, one, or two points in the following domains: history, EKG, age, risk factors, and troponin with a composite score of zero to ten. Low-risk patients with HS ≤3 are considered safe for outpatient evaluation. Prior studies show appropriate utilization of the HS reduces hospitalizations and unnecessary cardiac testing as well as healthcare cost. We conducted a retrospective chart review of young adults &lt;45 years of age, admitted from the emergency department (ED) with undifferentiated chest pain between August 2018 and September 2019. HS was calculated for each adult, and when available, compared to scores calculated by the ED. Patients were reviewed for 30 day MACE, HS accuracy, diagnostic testing, and hospitalization cost. Of our 150 admitted patients, 91 (60.7%) had a HS ≤3 representing a low-risk cohort. HS was calculated by the ED in 36 patients (24%), 11 of those 36 were low-risk. 23 out of 36 patients had scores different from our calculation. No MACE occurred in the low-risk group. A single angioplasty was performed in a patient with a HS of 5. Median charge on each admitted patient with HS ≤3 is $19,000, translating to 1.73 million dollars.In a rural community hospital, outpatient management of young adults age ≤45 with a HS≤3 appears safe and cost-effective. In our institution, the HS was underused with score variability among providers. We feel there is an opportunity to improve care and save money through proper implementation of the HS. This is achievable through education, standard protocols, and better communication among ED, in-patient, and ambulatory services.
Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain
Authors: Jonathan Daniel Ip, Kin-Hang Kok, Wan-Mui Chan, Allen Wing-Ho Chu, Wai-Lan Wu, Cyril Chik-Yan Yip, Wing-Kin To, Owen Tak-Yin Tsang, Wai-Shing Leung, Thomas Shiu-Hong Chik, Kwok-Hung Chan, Ivan Fan-Ngai Hung, Kwok-Yung Yuen, Kelvin Kai-Wang To
Journal: Clinical Microbiology and Infection (2020)
Stabilization of hypoxia-inducible factor ameliorates glomerular injury sensitization after tubulointerstitial injury
Authors: Jun Zou, Jaewon Yang, Xiaoye Zhu, Jianyong Zhong, Ahmed Elshaer, Taiji Matsusaka, Ira Pastan, Volker H. Haase, Hai-Chun Yang, Agnes B. Fogo
Journal: Kidney International (2020)
Abstract 524: Phosphofructokinase Coordinates Anabolic Pathways in the Heart
Authors: Kyle L Fulghum, Pawel K Lorkiewicz, Teresa Cassel, Teresa M Fan, Steven P Jones, Bradford G Hill
Journal: Circulation Research (2020)

Energy provision and biosynthesis are thought to be controlled by amphibolic enzymes such as phosphofructokinase (PFK). Nevertheless, it remains unclear how PFK influences collateral biosynthetic pathways in the heart. Here, we investigated the control exerted by PFK on anabolic pathways in the heart using in vivo deep network tracing. Wild-type (WT) mice and mice overexpressing kinase- or phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase transgenes, termed respectively Glyco Lo or Glyco Hi mice, were fed a liquid diet containing 13 C 6 -glucose for 18 h. From freeze-clamped hearts, metabolite abundance and 13 C enrichment were then assessed by ion chromatography-mass spectrometry. Compared with Glyco Hi and WT hearts, Glyco Lo hearts had remarkably higher levels and 13 C enrichment of glucose 6-phosphate, fructose 6-phosphate (F6P) (p&lt;0.01 each, n =4/gp), and purine and pyrimidine biosynthetic pathway intermediates. In addition to elevated activity of nucleotide biosynthetic pathways, we also found in Glyco Lo hearts higher 13 C-hexose incorporation into N-acetyl-D-glucosamine 6-phosphate (p&lt;0.05); however, the levels of UDP-GlcNAc and its enrichment with 13 C were not different between the groups, which suggests that PFK activity influences the hexosamine biosynthetic pathway primarily by modulating F6P incorporation. Whereas Glyco Lo hearts showed lower 13 C fractional enrichment in triacylglycerols and hexosyl ceramide species, Glyco Hi hearts showed higher 13 C fractional enrichment in ceramide species. Interestingly, Glyco Lo hearts had 2-fold lower levels of alpha-ketoglutarate with concomitant increases in glutamate abundance. Energy charge values ranged from 0.69-0.81 with no differences observed between groups.These results suggest that PFK regulates lipid biosynthesis and collateral biosynthetic pathways of glucose metabolism in the heart. Understanding how these pathways contribute to cardiac remodeling could be important for developing metabolic therapies to improve cardiac health.
Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT
Authors: Hengwei Wu, Jimin Shi, Yi Luo, Yamin Tan, Mingming Zhang, Xiaoyu Lai, Jian Yu, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
Journal: Blood (2020)
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Authors: Manuel J. Richter, Athiththan Yogeswaran, Khodr Tello
Journal: European Respiratory Journal (2020)

<b>The pulmonary physician must be aware of pulmonary toxicities if patients are treated with tyrosine kinase inhibitors. The compounds have different therapeutic targets and are associated to different extents with pulmonary complications.</b>https://bit.ly/3gXUF8h
Covid-19: Two fifths of doctors say pandemic has worsened their mental health
Authors: Abi Rimmer
Journal: BMJ (2020)

Covid-19: Two fifths of doctors say pandemic has worsened their mental health Abi RimmerMore than two fifths of doctors in the UK say that their mental health is now worse than before the pandemic, a BMA survey has found.The association received responses from 6610 doctors working across England to a snapshot survey it conducted in October.Of the 6550 doctors who responded to a question about their mental wellbeing, 43% said that they were currently experiencing work related depression, anxiety, stress, burnout, emotional distress, or other mental health condition and that it was worse than it had been before the pandemic started.A further 12% said they had a work related mental health problem but it was no different than it had been before the pandemic, while 39% said they did not have a work related problem, and 6% preferred not to say.Of 6559 doctors who responded to a follow-up question, a third (32%) said that their health and wellbeing were slightly worse than it had been during the first wave of the pandemic and 10% said it was much worse.More than a third (37%) said it was the same, while 21% said it was better.Doctors also expressed concern about how the service would cope with demand from patients for non-covid care during the second wave of the pandemic.Of the 6125 doctors who responded to the question, most (72%) said that they were not confident that social care would cope, while two thirds (65%) were not confident in their own local healthcare service's ability to cope.Chaand Nagpaul, chair of the BMA council, said the findings showed the enormous scale of the challenges the NHS would face in the coming months and reinforced the BMA's call for a national and strategic approach to getting covid-19 under control.
Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)
Authors: Timothy S. Pardee, Kristin M. Pladna, Susan Lyerly, Sarah Dralle, Megan Manuel, Leslie Renee Ellis, Dianna S. Howard, Rupali Bhave, Bayard L. Powell
Journal: Blood (2020)
Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and <i>De Novo</i> Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group
Authors: Romain Morizot, Sebastien Hergalant, Romain Piucco, Florian Bouclet, Anne Quinquenel, Caroline Dartigeas, Hélène Augé, Eugen Tausch, Sandra Lomazzi, Hélène Busby, Cécile Tomowiak, Veronique Leblond, Catherine Thieblemont, Florence Cymbalista, Marie C Bene, Stephan Stilgenbauer, Romain Guieze, Christine Carapito, Aurore Perrot, Luc Mathieu Fornecker, Pierre Feugier, Julien Broséus
Journal: Blood (2020)
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Authors: Chaitra S. Ujjani, Catherine Lai, Lori A. Leslie, Pari Ramzi, Ming Tan, Siyu Wang, Hongkun Wang, Eunice Shim, Nicole Swanson, Catherine M Broome, Ajay K. Gopal, Stephen D. Smith, Edus H. Warren, Katie Blue, Sabrina Kdiry, Brian G. Till, Ryan C. Lynch, Mazyar Shadman, Michael Johnson, Hilary Coye, Megan Shelby, Yolanda D. Tseng, Andrei Shustov, David G. Maloney, Bruce D. Cheson
Journal: Blood (2020)
Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study
Authors: Qingqing Cai, Huiqiang Huang, Panpan Liu, Hui Zhou, Yajun Li, Yujing Zhang, Lixia Lu, Yan Gao, Xuanye Zhang, Yi Xia, Jun Cai, Ning Su, Shuyun Ma, Hang Yang, Yu Fang
Journal: Blood (2020)